Review
Nutrition & Dietetics
Justyna Paulina Wielgosz-Grochowska, Nicole Domanski, Malgorzata Ewa Drywien
Summary: Small intestinal bacterial overgrowth (SIBO) is common in irritable bowel syndrome (IBS). Antibiotic treatment is the first-line approach, but focusing solely on antimicrobial effects without considering lifestyle factors and dietary patterns may lead to intestinal microbiota dysfunction. Recent studies suggest that dietary manipulation can alleviate SIBO gastrointestinal symptoms, but the efficacy of the IBS diet in SIBO remains largely hypothetical and further research is needed to establish a specific diet for SIBO treatment.
Review
Biochemistry & Molecular Biology
Agnieszka Chlebicz-Wojcik, Katarzyna Slizewska
Summary: Irritable bowel syndrome is not life-threatening but significantly impacts quality of life and economic loss. Research focuses on the role of intestinal microbiota in disease development, with an emphasis on therapies modulating the microbiota such as probiotics, prebiotics, and synbiotics. Most studies have focused on probiotics, but there are also promising results from studies on prebiotics and synbiotics.
Article
Chemistry, Multidisciplinary
Ji-Yan Qiao, Run-Yao Zeng, Qi-Wen Chen, Diwei Zheng, Pei-Ling Hao, Xin-Hua Liu, Faqiong Zhao, Xian-Zheng Zhang
Summary: A prebiotic-probiotic living capsule (PPLC) was constructed by coculturing probiotics and Gluconacetobacter xylinus in a prebiotic-containing fermentation broth. The shaking of the culture led to the secretion of cellulose fibrils by G. xylinus, which could spontaneously encapsulate probiotics to form microcapsules under shear forces. The microcapsules, containing dense colonies of probiotics, demonstrated excellent therapeutic performance in treating enteritis mice.
Review
Microbiology
Rachel Goodman-Davis, Marianna Figurska, Anna Cywinska
Summary: Diarrhea in foals is a significant issue that may be influenced by microbiota manipulation, but caution should be exercised in using prebiotics and probiotics.
Review
Biochemistry & Molecular Biology
Davide Banfi, Elisabetta Moro, Annalisa Bosi, Michela Bistoletti, Silvia Cerantola, Francesca Crema, Fabrizio Maggi, Maria Cecilia Giron, Cristina Giaroni, Andreina Baj
Summary: This article discusses the role of the microbiota-gut-brain axis in the pathogenesis of Inflammatory Bowel Disease (IBD) and the impact of microbial-derived metabolites on the development of IBD-related symptoms. It points out that mood disorders and heightened stress responses may affect the severity of IBD.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Bridgette Wilson, Tokuwa Kanno, Rachael Slater, Megan Rossi, Peter M. Irving, Miranda C. Lomer, Chris Probert, A. James Mason, Kevin Whelan
Summary: Baseline faecal and urine metabolites can predict response to the low FODMAP diet in patients with irritable bowel syndrome.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Biochemistry & Molecular Biology
Flavia di Michele
Summary: This review summarizes the current evidence of nutraceutical supplementation in the treatment of irritable bowel syndrome (IBS), including probiotics, prebiotics, synbiotics, butyrate, palmitoylethanolamide, and colostrum. These compounds have multiple mechanisms of action and show good safety and tolerability profiles. Though further studies are needed to strengthen the evidence, supplementation with these compounds may be useful, especially for special populations of patients, and is more readily accepted by patients compared to pharmacological therapy.
CURRENT MEDICINAL CHEMISTRY
(2022)
Review
Microbiology
Tarek Mazzawi
Summary: Research suggests that manipulating gut microbiota can improve symptoms of irritable bowel syndrome (IBS), with dietary management and other approaches showing promise in changing gut composition and alleviating IBS symptoms. However, more research is needed to identify the exact mixture of beneficial bacteria.
Review
Medicine, General & Internal
Flavia Maria Pavel, Cosmin Mihai Vesa, Gina Gheorghe, Camelia C. Diaconu, Manuela Stoicescu, Mihai Alexandru Munteanu, Elena Emilia Babes, Delia Mirela Tit, Mirela Marioara Toma, Simona Bungau
Summary: Inflammatory bowel disease (IBD) encompasses Crohn's disease (CD) and ulcerative colitis (UC), characterized by chronic gut inflammation due to genetic predisposition and environmental factors. Microbial studies have identified the role of gut microbiome in IBD pathophysiology, highlighting the importance of microbiome management in treatment, with probiotics and prebiotics showing beneficial effects.
Review
Biochemistry & Molecular Biology
Yuri Haneishi, Yuma Furuya, Mayu Hasegawa, Antonio Picarelli, Mauro Rossi, Junki Miyamoto
Summary: Inflammatory bowel disease (IBD) is a rapidly increasing inflammatory disease of the gastrointestinal tract worldwide. Recent research suggests that factors such as genetics, environment, microbiota, and immune responses are involved in its development, but the underlying causes are unclear. Dysbiosis of gut microbiota, particularly a decrease in specific genera, has been identified as a possible trigger for IBD. Improving gut microbiota and identifying specific bacterial species are crucial for understanding and treating IBD and autoimmune diseases.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Nutrition & Dietetics
Xiao-Feng Zhang, Xiao-Xian Guan, Yu-Jun Tang, Jin-Feng Sun, Xiao-Kai Wang, Wei-Dong Wang, Jian-Ming Fan
Summary: The study found that probiotics, prebiotics, and synbiotics can induce/maintain IBD remission and reduce the disease activity index of UC. Probiotic supplements can increase beneficial bacteria (especially Bifidobacteria) in the gut of patients with IBD to some extent.
EUROPEAN JOURNAL OF NUTRITION
(2021)
Review
Immunology
Jongwook Yu, Jae Hee Cheon
Summary: Gut dysbiosis is a prominent feature in inflammatory bowel diseases (IBDs) with unknown causes. Research has focused on managing IBD by modulating and correcting gut dysbiosis, using methods such as antibiotics, probiotics, prebiotics, and fecal microbiota transplantation. However, studies on specific changes in the gut microbiota depending on the treatment options are limited.
Article
Microbiology
Joann Phan, Divya Nair, Suneer Jain, Thibaut Montagne, Demi Valeria Flores, Andre Nguyen, Summer Dietsche, Saurabh Gombar, Philip Cotter
Summary: Irritable bowel syndrome (IBS) is characterized by abdominal discomfort and irregular bowel movements, with the gut microbiome posited to play a significant role. This study analyzed stool samples from individuals with IBS and without IBS and found differences in microbial features, with synbiotic supplementation showing potential to impact these features. Further research is needed to determine the relationship between microbiome changes and improvement in IBS symptoms.
Article
Multidisciplinary Sciences
Binbin Tang, Yunlian Hu, Jianhui Chen, Chengxia Su, Qian Zhang, Chaoqun Huang
Summary: This study investigated the characteristics and correlation between oral (tongue coating) and fecal microbiota in patients with diarrheal irritable bowel syndrome (IBS-D). The microbial richness of tongue coating in IBS-D patients was lower than that in the normal control group. The oral and fecal microbiotas of IBS-D patients differ from those of the control group.
Article
Biochemistry & Molecular Biology
J. I. Ramirez-Perez, M. Abud-Archila, S. L. Ovando-Chacon, R. E. Soria-Guerra, M. A. Ruiz-Cabrera, C. I. Godinez-Hernandez, A. Grajales-Lagunes
Summary: A completely randomized experimental design was conducted to evaluate the effect of coadministration of Lpb. fabifermentans and inulin/agave fructans mixtures on gut microbiota. The results showed that the combination of fructan mixtures and Lpb. fabifermentans significantly decreased glucose, cholesterol, and triglycerides levels, and improved short-chain fatty acids concentration throughout the gastrointestinal tract. It also promoted an increase in the abundance of beneficial intestinal microbiota. Therefore, the inclusion of fructan mixtures in combination with Lpb. fabifermentans could be a good alternative for the development of functional foods that enhance consumer health.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2023)